70% to 85% of Americans need to be fully vaccinated for a return to normal, Fauci says. So far it’s less than 2%

(CNN) About 70% to 85% of the US population should be fully vaccinated against Covid-19 before the country can begin to return to a sense of normalcy, Dr. Anthony Fauci told CNN Tuesday night.

So far, less than 2% of Americans have received both doses of a Covid-19 vaccine, according to data from the Centers for Disease Control and Prevention.
Across the US, more than 32.7 million Covid-19 vaccine doses have been administered, with about 26.4 million people having received at least one dose. About six million people have received both doses, the CDC data shows.

Fauci said he’s hopeful the country can get to that high level of vaccinations by the end of the summer to the beginning of fall.

“Having said that,” he added, “There is an absolute ‘but’ in that. And the ‘but’ is that we have to address the variants.”Experts have sounded the alarm about the new Covid-19 variants that have been detected in the US, warning the country is now in a race against time to vaccinate as many people as possible before the variants spread too far and possibly trigger another surge of infections.

Read further

Categories: Vaccine

9 replies

  1. The team of researchers at Imperial College London used cell phone location data covering more than 10 million people and publicly available information on the spread of the virus to calculate which age groups were most responsible.

    They estimated that people 35 to 49 accounted for 41% of the new transmissions through mid-August, and adults 20 to 34 were responsible for another 35%. Children and teens accounted for just 6% of spread. while people 50 to 64 made up 15% of transmission.

    Experts have previously warned that the surges were largely driven by younger groups, Fauci said, but that doesn’t mean those groups should get the vaccine “at the expense of getting the older people who have the underlying conditions, get vaccinated.”

  2. GlaxoSmithKline Plc and CureVac NV joined forces to create next-generation messenger RNA vaccines to combat emerging variants of the coronavirus that could make the first shots less effective.

    The companies aim to have a candidate approved by 2022 as part of a 150 million euro ($180 million) collaboration, according to a statement Wednesday. Glaxo this year also plans to help manufacture as many as 100 million doses of CureVac’s current mRNA Covid-19 vaccine, which is still in late-stage trials and could be approved as soon as March.

    Drugmakers are racing to catch up with the virus amid concern that new and potentially more dangerous variants might diminish the effectiveness of some vaccines. In helping CureVac manufacture its current shot, the British pharma giant follows Sanofi, Novartis AG and Bayer AG in throwing its weight behind another company’s Covid vaccines, potentially accelerating the rollout.

    The partners aim to use novel mRNA technology to develop products that target multiple variants in one vaccine. The immunizations may be used to protect people who haven’t been inoculated or as booster shots if immunity from other vaccines wanes, they said. The pair will also investigate mRNA vaccines to protect against other respiratory viruses beyond Covid-19.


  3. Two weeks after Joe Biden became president, his administration announced its biggest breakthrough yet in distributing Covid-19 vaccines. But Biden didn’t share the good news himself.

    Instead, the Tuesday briefing came from a 54-year-old former business executive and Biden ally named Jeff Zients, who is unfamiliar to most Americans.

    The arrival of Zients as Biden’s Covid-19 czar comes as the president has put beating the pandemic — an incredibly complex and demanding goal — at the top of his priority list. It’s a posting that will test a reputation Zients has built with Democrats inside the Washington Beltway as the go-to-guy when things go awry.

    Zients doesn’t have a medical or military background, like the two men who ran Operation Warp Speed in the Trump Administration. But the former Bain & Co. consultant is well regarded for his organizational and planning skills, particularly among those who served with him during the Obama-Biden administration.


  4. At the same time, the White House announced on Tuesday that it was enlisting more retail pharmacies as a channel to distribute vaccines. Jeffrey D. Zients, the White House’s coronavirus response coordinator, said the federal government would send a million doses to around 6,500 retail pharmacies on Feb. 11, the beginning of a federal program that eventually is expected to deliver vaccines directly to 40,000 pharmacies.

  5. (CNN)In December, President Joe Biden set a vaccination target of 100 million doses in his first 100 days. During his first week in office, however, healthcare workers were already meeting the goal of administering an average of 1 million doses a day. While Biden has already raised the bar, saying he hopes to get to 1.5 million doses a day, the new administration can and should do more to accelerate the vaccine rollout.

    The Trump administration’s abject failure to coordinate a federal strategy means we are facing immediate bottlenecks in vaccine distribution, but in the medium term, manufacturing capacity could become the primary barrier to accelerating vaccinations. The New York Times reported last month that manufacturing limitations make it impossible to increase the supply before April, while the largest vaccine manufacturer in the world estimated in September that it would take until 2024 at the earliest to vaccinate everyone on Earth.

    With the spread of Covid-19 expected to accelerate due to new and more transmissible strains, speeding up the vaccine timeline by even a few months could save thousands of lives (as well as hundreds of billions of dollars in recovered economic activity, according to Oxford economist Gregory Daco). The appearance of strains that could partially resist the current vaccines makes scaling vaccine production even more urgent: The longer we wait to vaccinate everyone, the more we risk resistant strains evolving and spreading, prolonging the pandemic and necessitating further rounds of vaccination. It’s time to get much more ambitious about making vaccines.


  6. The U.S. is on pace to vaccinate 75% of its population against Covid-19 this year, while Canada would need almost a decade to reach that coverage level, according to Bloomberg’s Covid-19 Vaccine Tracker.

    The starkly different trajectories show how unevenly countries around the world have kicked off the largest mass vaccination drive in history. The U.K. and Israel are also on a path to administer a two-dose vaccine regimen to three-quarters of people this year — reaching a rough estimate for when herd immunity might kick in — while much of Europe would need a few years for that.

    Though overall the U.S. is faring relatively well compared with other countries, the picture varies by individual states. Hawaii is headed for the key coverage level this year, with New York currently looking at summer 2022.


  7. United Nations: The Serum Institute of India (SII) and UNICEF have entered into a long-term supply agreement for the AstraZeneca-Oxford ‘Covishield’ and the Novavax vaccines, with the UN children’s agency saying it will have access to up to 1.1 billion doses of vaccines for around 100 countries.
    India is one of the world’s biggest drugmakers, and an increasing number of countries have already approached it for procuring the coronavirus vaccines.

    While Oxford-AstraZeneca’s Covishield is being manufactured by Pune-based Serum Institute, and the Novavax is being produced by US-based Novavax Inc.

    “Today we are pleased to announce the conclusion of a long-term supply agreement with the Serum Institute of India for COVID-19 vaccines, to access two vaccine products through technology transfer from ASTRAZENECA and NOVAVAX,” the United Nations International Children Education Fund (UNICEF) Executive Director Henrietta Fore said.

    Ms Fore added that UNICEF, along with its procurement partners including Pan American Health Organisation (PAHO), will have access to up to 1.1 billion doses of vaccines for around 100 countries, for approximately USD 3 a dose for the low- and lower middle-income countries.

    This is great value for COVAX donors and a strong demonstration of one of the fundamental principles of COVAX – that by pooling our resources we can negotiate in bulk for the best possible deals, she said.

    She added that as these supply agreements are concluded, UNICEF will continue to make public relevant details of the agreements, subject to the consent of the suppliers.

    Likewise, we look forward to working with SII to distribute these vaccines to countries, subject to the approval of the vaccine by World Health Organisation.

    Key workers and other vulnerable people in 145 countries should receive COVID-19 vaccines in the first half of this year, under the joint UN-led COVAX initiative for fair access to coronavirus-beating jabs.


  8. ISLAMABAD – Pakistan announced Saturday it has secured 17 million doses of AstraZeneca’s coronavirus vaccine through the World Health Organization’s COVAX program to vaccinate its citizens against COVID-19.

    Additionally, the government said, a plane will fly to China on Sunday to airlift an initial tranche of the 500,000 doses of Chinese Sinopharm vaccine Beijing has gifted to Islamabad.

    The coronavirus pandemic in Pakistan, a country of about 220 million people, is relatively under control. The South Asian nation detected the outbreak nearly a year ago and has since documented more than 543,000 confirmed COVD-19 cases, with close to 12,000 deaths.

    Dr. Faisal Sultan, special health assistant to the prime minister, said Saturday that almost seven million doses of AstraZeneca’s vaccine will be available for Pakistani citizens in the first quarter of the year and the rest within the second quarter of 2021.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.